Acrux Stock

Acrux Revenue

The The revenue of Acrux (ACR.AX) as of Aug 17, 2026 is 4.53 M AUD. In the previous year, The revenue was 8.10 M AUD — a change of -44.08% (lower).

Revenue

4.53 MAUD

YoY

-44.08%

Last updated:

In 2026, Acrux's sales reached 4.53 M AUD, a -44.08% difference from the 8.10 M AUD sales recorded in the previous year.

Over the last 19 years Acrux grew revenue by 2.6% annually, reaching 4.53 M AUD.

The Acrux Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

REVENUE (M AUD)
GROSS MARGIN (%)
Date
REVENUE (M AUD)
GROSS MARGIN (%)
Jan 1, 2020
3.85 base
117.76 base
Jan 1, 2021
4.79 base
94.49 base
Jan 1, 2022
5.10 base
88.73 base
Jan 1, 2023
11.93 base
95.32 base
Jan 1, 2024
8.10 base
51.14 base
Jan 1, 2025
4.53 base
100.00 base
Jan 1, 2026 (e)
20.34 base
22.26 base
Jan 1, 2027 (e)
15.00 base
30.18 base
YEARREVENUE (M AUD)GROSS MARGIN (%)
2027 est 15.0030.18
2026 est 20.3422.26
2025 4.53100.00
2024 8.1051.14
2023 11.9395.32
2022 5.1088.73
2021 4.7994.49
2020 3.85117.76
2019 5.29100.00
2018 3.4398.54
2017 23.9399.43
2016 28.5696.54
2015 25.2096.59
2014 53.8696.60
2013 16.5396.79
2012 10.4797.42
2011 93.4796.78
2010 56.1096.60
2009 2.90156.14
2008 7.0564.23
2007 5.1388.27
2006 2.80161.71
Access this data via the Eulerpool API
Get Free API Key

Acrux Revenue

Acrux Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.85 M AUD
-9.49 M AUD
-9.47 M AUD
Jan 1, 2021
4.79 M AUD
-12.80 M AUD
-12.63 M AUD
Jan 1, 2022
5.10 M AUD
-9.58 M AUD
-9.83 M AUD
Jan 1, 2023
11.93 M AUD
109,000.00 AUD
-764,000.00 AUD
Jan 1, 2024
8.10 M AUD
-5.57 M AUD
-5.80 M AUD
Jan 1, 2025
4.53 M AUD
-5.63 M AUD
-5.95 M AUD
Jan 1, 2026 (e)
20.34 M AUD
10.37 M AUD
12.77 M AUD
Jan 1, 2027 (e)
15.00 M AUD
5.18 M AUD
6.33 M AUD

Acrux Margins

Acrux stock margins

The Acrux margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acrux. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acrux.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-246.68 %
-246.32 %
Jan 1, 2021
100.00 %
-267.03 %
-263.54 %
Jan 1, 2022
100.00 %
-187.77 %
-192.71 %
Jan 1, 2023
95.32 %
0.91 %
-6.41 %
Jan 1, 2024
51.14 %
-68.76 %
-71.62 %
Jan 1, 2025
100.00 %
-124.40 %
-131.29 %
Jan 1, 2026 (e)
100.00 %
50.99 %
62.78 %
Jan 1, 2027 (e)
100.00 %
34.51 %
42.20 %

Acrux Stock analysis

What does Acrux do? Acrux Ltd is an Australian pharmaceutical company specializing in the development and marketing of products in the dermatology field. The company was founded in 1998 and is headquartered in Melbourne. Its history begins with the development of a groundbreaking technology called the "Sprayform® Technology," which allows the administration of liquid medications in spray form, providing numerous advantages compared to traditional administration methods. Acrux obtained the first patent for this technology in 1999 and worked on bringing it to the market. Its business model focuses on licensing its Sprayform® Technology to third parties to advance the development and marketing of products in various therapeutic areas. The company has an experienced research and development team that collaborates closely with partners to develop tailored solutions and support the entire development process, ensuring that all products meet the highest quality standards and regulatory requirements. Acrux Ltd is divided into various divisions, including products for women, diabetes, pain and inflammation, as well as neurology and psychiatry. With its Sprayform® Technology, the company has developed unique therapeutic solutions that meet patients' needs. For example, a testosterone preparation for women has been developed that is simply applied as a spray and offers higher efficacy than traditional tablets. Another product is a fast-acting pain reliever that is administered through a nasal spray. Acrux Ltd also has partnerships with major pharmaceutical companies such as Eli Lilly, Johnson & Johnson, Pfizer, and Sanofi. These partnerships enable Acrux to market its technology globally and offer its customers a comprehensive portfolio of tailored solutions. The partner is granted exclusive rights to use the technology for specific products and markets, facilitating the development of new products and the expansion into new regions. Overall, Acrux Ltd has achieved a leadership position in the field of transdermal systems and transmucosal technologies through its innovative Sprayform® Technology. The company aims to further expand its leadership position by focusing on the development of new products and collaboration with partners. Acrux remains in constant exchange with the scientific community to incorporate the latest research and development insights into its products. Acrux is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Acrux's Sales Figures

The sales figures of Acrux originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Acrux’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Acrux's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Acrux’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Acrux stock

The revenue of Acrux is 4.53 M AUD in 2026.

The revenue of Acrux changed from 8.10 M AUD to 4.53 M AUD, representing a -44.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue Acrux since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Acrux historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Acrux

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Acrux